<- All drugs

Lotiglipron

DISCONTINUED

Oral non-peptide GLP-1 receptor agonist

graded results

ongoing records

effect domains

Evidence spread

High evidence 0Moderate evidence 0Low evidence 1Very low evidence 2

Lotiglipron has a discontinued status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

DISCONTINUED Global programme; Obesity and type 2 diabetes; Oral tablet; as of 2026-07-13. Pfizer

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Lotiglipron DISCONTINUED

pharmacology Not directional

Low evidence

Oral non-peptide GLP-1RA (PF-07081532, Pfizer/Sosei Heptares). Two phase 1 MAD studies in T2D and obesity reported PK/PD signals. Development DISCONTINUED June 2023 on...

Buckeridge et al., Diabetes Obes Metab 2024 (phase 1); Pfizer update June 2023 Source

Full findingOral non-peptide GLP-1RA (PF-07081532, Pfizer/Sosei Heptares). Two phase 1 MAD studies in T2D and obesity reported PK/PD signals. Development DISCONTINUED June 2023 on elevated transaminases in phase 1 DDI studies and ongoing phase 2 (transaminase elevation 6.0-6.6% on lotiglipron vs 1.6% placebo, obesity cohort); no liver symptoms/failure. Pfizer noted such elevations had not been seen with danuglipron at that time.

PopulationTwo phase 1 randomised placebo-controlled MAD studies in T2D and obesity; plus ongoing phase 2

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Lotiglipron DISCONTINUED

safety-other Increase

Very low evidence

Elevated liver enzymes observed in clinical testing, leading to discontinuation of the entire program in 2023.

Pfizer / BioPharma Dive: Pfizer, citing safety concerns, scraps one of two obesity pill h... Source

PopulationPfizer phase 1/2 lotiglipron program (obesity and T2D)

Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Lotiglipron DISCONTINUED

weight-loss Not directional

Very low evidence

Weight-loss/glycaemic efficacy was being evaluated in mid-stage trials but development halted before mature efficacy data were published.

Pfizer press / CNBC: Pfizer to end development of experimental obesity pill lotiglipron, ... Source

PopulationPhase 1/2 (obesity, T2D); halted 2023

Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)